X

Trial Profile

A Phase 1b/2 Trial of Lurbinectedin Plus Doxorubicin in Leiomyosarcoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin (Primary) ; Lurbinectedin (Primary)
Indications Leiomyosarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma; Solitary-fibrous-tumour
Focus Adverse reactions; Therapeutic Use

Most Recent Events

30 Oct 2023 Planned End Date changed from 1 Jan 2025 to 1 Jul 2025.
30 Oct 2023 Planned primary completion date changed from 1 Jan 2024 to 1 Jul 2024.
06 Jun 2023 The phase 2 of this trial began accrual in Aug 2022 aiming to enroll 50 leiomyosarcoma patients randomized 1:1 (stratified by uterine leiomyosarcoma versus other leiomyosarcoma), as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com